In the next few weeks I plan to highlight under-appreciated and under-followed biotech companies-the first of which is OncoGenex (NASDAQ:OGXI). These names represent a significant profit potential for those who have a longer-term perspective. Too many traders have a very short hold period and, in turn, miss opportunities that Endocyte (NASDAQ:ECYT) or Pharmacyclics (NASDAQ:PCYC) can give their portfolio over a period of 1-3 years.
As the first installment in this series of CEO interviews, I would like to introduce OncoGenex CEO Scott Cormack and show how he has built a unique cancer biotechnology company. This exclusive interview with Mr. Cormack makes a case that OncoGenex is a bargain-buy at today's price levels.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|